华东医药重磅新药获批上市10月24日,国家药监局官网显示,华东医药全资子公司杭州中美华东制药申报的1类新药马来酸美凡厄替尼片获批上市,适应症为:用于表皮生长因子受体(EGFR)21号外显子L858R置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。截图来源:国家药监局官网公开资料显示,马来酸美凡厄替尼是一款新型、强效、高选择性、具有口服活性的不可逆EGFR/HER2小分子...
Source Link华东医药重磅新药获批上市10月24日,国家药监局官网显示,华东医药全资子公司杭州中美华东制药申报的1类新药马来酸美凡厄替尼片获批上市,适应症为:用于表皮生长因子受体(EGFR)21号外显子L858R置换突变的局部晚期或转移性非小细胞肺癌(NSCLC)成人患者的一线治疗。截图来源:国家药监局官网公开资料显示,马来酸美凡厄替尼是一款新型、强效、高选择性、具有口服活性的不可逆EGFR/HER2小分子...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.